Patents Examined by Kamal A. Saeed
  • Patent number: 10703845
    Abstract: Monomer compounds and methods of synthesizing monomer compounds are disclosed. The monomer compounds can include maleate and maleimide monomers having fatty acid moieties. The monomer compounds can be derived from renewable sources such as corn, soybean, and sunflower oils. The monomer compounds can be formed into homopolymers as well as copolymers. The copolymers can include petroleum-derived monomers such as styrene, ethylene, and propylene.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 7, 2020
    Assignee: University of South Carolina
    Inventors: Chuanbing Tang, Liang Yuan, Meghan Lamm
  • Patent number: 10695323
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 30, 2020
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Patent number: 10689372
    Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 23, 2020
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
  • Patent number: 10689346
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: June 23, 2020
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • Patent number: 10688081
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 23, 2020
    Assignee: SABRE THERAPEUTICS LLC
    Inventors: John Howard Hutchinson, David Lonergan
  • Patent number: 10683271
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 16, 2020
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully
  • Patent number: 10676423
    Abstract: Methods of synthesizing polyfluorinated amino acid derivatives are disclosed, along with polyfluorinated amino acid derivatives produced from said methods, as well as compositions containing same. The synthesis methods utilize an oxazolone and a perfluoroarene to produce the polyfluorinated amino acid derivatives.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 9, 2020
    Assignee: The Board of Regents for Oklahoma State University
    Inventors: Jimmie Dean Weaver, Kip Allen Teegardin, Amandeep Arora
  • Patent number: 10676439
    Abstract: A pyridine compound having a SF5 group on position-3 and position-4 of a pyridine ring is provided.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: June 9, 2020
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Norio Shibata, Kohei Matsuzaki, Norimichi Saito
  • Patent number: 10668051
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 2, 2020
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Gayatri S. Merikapudi, Swaroop K. Vakkalanka
  • Patent number: 10662160
    Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 26, 2020
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Yahya El-Kattan, Yarlagadda S. Babu
  • Patent number: 10662333
    Abstract: The invention relates to a porphyrin time domain indicator. The indicator may be used for detection of a particular analyte in vivo or in vitro. The indicator may be used for detection of glucose in vivo or in vitro.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 26, 2020
    Assignee: Profusa, Inc.
    Inventor: Arthur E. Colvin, Jr.
  • Patent number: 10653146
    Abstract: Compounds of Formula (I) wherein the substituents are as defined claim 1, useful as pesticides, especially as fungicides.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 19, 2020
    Assignee: Syngenta Participations AG
    Inventors: Thomas James Hoffman, Daniel Stierli, Renaud Beaudegnies, Martin Pouliot, Thomas Pitterna
  • Patent number: 10654801
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: May 19, 2020
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian, Shengliang Zhang
  • Patent number: 10654868
    Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 19, 2020
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Lun Lu, Zhibo Zhang, Gang Li, Lihong Hu, Charles Z. Ding, Shuhui Chen
  • Patent number: 10647658
    Abstract: Aspects of the present disclosure include fatty acid ?-hydroxyester compounds (e.g., fatty acid esters of ?-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid ?-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 12, 2020
    Assignees: The J. David Gladstone Institutes, The Regents of The University Of California, Ithaca College
    Inventors: Eric Verdin, Scott Michael Ulrich, John C. Newman
  • Patent number: 10633345
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: April 28, 2020
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • Patent number: 10633337
    Abstract: The present invention belongs to the field of pharmaceutical technology, and crystal forms of a 9-aminomethyl substituted tetracycline compound and a process for preparing the same. More specifically, the present invention relates to crystal forms of the compound represented by formula (1), a process for preparing crystal forms of the compound represented by formula (1) and use of said crystal forms in manufacture of medicament for treating and/or preventing an infection disease caused by tetracycline-sensitive bacteria and/or tetracycline-resistant bacteria.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 28, 2020
    Assignee: KBP Biosciences Co., Ltd.
    Inventors: Zhenhua Huang, Mei Hong, Chen Jiang
  • Patent number: 10633395
    Abstract: The invention relates to aryloxazolidinone compounds of formula I: wherein Y represents hydrogen or certain chemical groups. These compounds are useful antimicrobial agents effective against a variety of pathogens including inter alia Gram-negative aerobic and anaerobic bacteria.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: April 28, 2020
    Assignee: Idorsia Pharmaceuticals Ltd.
    Inventors: Daniel Ritz, Georg Rueedi, Cornelia Zumbrunn
  • Patent number: 10618879
    Abstract: Provided herein are improved processes for converting C7-amino-substituted tetracyclines to C7-fluoro-substituted tetracyclines, as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is heated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C7-diazo-substituted tetracycline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is irradiated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: April 14, 2020
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Wu-Yan Zhang, Danny LaFrance, Magnus P. Ronn
  • Patent number: 10604495
    Abstract: The present invention relates to a process for preparing substituted phenylisoxazoline derivatives.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 31, 2020
    Assignee: Bayer Cropscience Aktiengesellschaft
    Inventors: Christian Funke, Jens Dietmar Heinrich, Sergii Pazenok, Norbert Lui